National Bank of Canada
GPCR icon

National Bank of Canada’s Structure Therapeutics GPCR Stock Holding History

National Bank of Canada’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Buy
305,400
+40,000
+15% +$2.74M 0.01% 578
2025
Q4 		$18.5M Buy
265,400
+121,400
+84% +$4.96M 0.02% 540
2025
Q3 		$4.03M Buy
144,000
+143,800
+71,900% +$2.86M ﹤0.01% 921
2025
Q2 		$4.15K Sell
200
-2,757
-93% -$60.6K ﹤0.01% 2521
2025
Q1 		$51.1K Buy
2,957
+2,766
+1,448% +$67.8K ﹤0.01% 1879
2024
Q4 		$5.18K Sell
191
-21
-10% -$745 ﹤0.01% 2445
2024
Q3 		$9.3K Buy
+212
New +$8.2K ﹤0.01% 2096

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

National Bank of Canada's GPCR Position: Q1 2026 in Review

National Bank of Canada increased its Structure Therapeutics (GPCR) stake by 15% in Q1 2026, buying an estimated $2.74M and bringing the position to 305,400 shares worth $14.7M. The position accounts for 0.01% of the portfolio, ranked #578.

National Bank of Canada first reported a position in GPCR in Q3 2024 and has held it in 7 quarters since. The position peaked at $18.5M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • National Bank of Canada held 305,400 shares of Structure Therapeutics worth $14.7M as of Q1 2026.
  • National Bank of Canada bought 40,000 Structure Therapeutics shares in Q1 2026, an estimated $2.74M.
  • Structure Therapeutics made up 0.01% of National Bank of Canada's portfolio in Q1 2026, its #578 holding.
  • National Bank of Canada first reported a position in Structure Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • National Bank of Canada's Structure Therapeutics position peaked at $18.5M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.